# Max Mikheev

> Max Mikheev is a molecular biologist, software-minded researcher, and the founder, CEO, and chief science officer of BIOMEDICAN. His career has moved from virology and genomics in Russia through computational biomedical research in the United States to engineering Yarrowia lipolytica yeast as a production platform for high-value compounds. The most concrete record of that work is a growing patent portfolio, including U.S. patents for producing cannabinoids in yeast.

- **Role:** Founder, CEO and Chief Science Officer at BIOMEDICAN, Inc.
- **Organizations:** BIOMEDICAN, Inc., BioDatomics, BioSof, National Institute on Aging, University of Pittsburgh School of Medicine, Research Institute of Clinical and Experimental Lymphology, State Research Center of Virology and Biotechnology VECTOR
- **Education:** PhD in Molecular Biology, State Research Center of Virology and Biotechnology VECTOR, MD in Clinical and Laboratory Diagnostics, Novosibirsk State Medical University, MSc in Molecular Biology, Novosibirsk State University
- **Known for:** Named inventor or co-inventor on biotechnology patents spanning viral identification, biological engineering and cannabinoid biosynthesis., Co-authored peer-reviewed work in virology, systems biology and computational biomedical modeling., Co-founded BioDatomics, described publicly as an early Hadoop-based genomic analysis platform.

## Career timeline

- **1999-2004** — Completed doctoral and medical training in molecular biology and clinical laboratory diagnostics while working in the Novosibirsk research ecosystem.
- **2001-2011** — Co-authored research on orthopoxvirus identification, viral genomics, agent-based biomedical modeling and cellular rhythm modeling.
- **2008-2010** — Worked on SPARK, a cross-platform system for agent-based modeling.
- **2011-2017** — Worked on the BioDatomics project and co-founded the genomic data-analysis company.
- **2012** — Became CTO and co-founder of BioDatomics.
- **2017** — Founded BIOMEDICAN in California.
- **2020** — BIOMEDICAN’s first U.S. patent application for producing cannabinoids in yeast was published.
- **2021** — U.S. Patent 11,149,291, Production of Cannabinoids in Yeast, was granted to BIOMEDICAN.
- **2024** — U.S. Patent 11,939,613, also covering production of cannabinoids in yeast, was granted to BIOMEDICAN.

## Achievements

- Named inventor or co-inventor on biotechnology patents spanning viral identification, biological engineering and cannabinoid biosynthesis.
- Co-authored peer-reviewed work in virology, systems biology and computational biomedical modeling.
- Co-founded BioDatomics, described publicly as an early Hadoop-based genomic analysis platform.
- Founded BIOMEDICAN and led development of its patented yeast-based biosynthesis platform.
- Co-inventor on U.S. Patent 11,149,291 and U.S. Patent 11,939,613 for production of cannabinoids in yeast.

## Latest updates

- **2024-08** — A continuation application for Production of Cannabinoids in Yeast was published as US20240279694A1, naming Maxim Mikheev and Difeng Gao as inventors.
- **2024-03** — U.S. Patent 11,939,613 for Production of Cannabinoids in Yeast was granted to BIOMEDICAN, naming Maxim Mikheev and Difeng Gao as inventors.
- **2022-12** — A BIOMEDICAN application titled Production of Cannabinoids was published as US20220403346A1, naming Maxim Mikheev as inventor.
- **2021-10** — U.S. Patent 11,149,291 for Production of Cannabinoids in Yeast was granted to BIOMEDICAN.

## Links

- Website: https://biomedican.com
- LinkedIn: https://www.linkedin.com/in/maxmikheev

---

Profile page: https://yespress.io/max-mikheev
Published by YesPress — https://yespress.io
Last updated: 2026-08-27